Publication/Creation Date

July 18 2019

Creators/Contributors

Tina Caliendo (creator)
Olga Hilas (creator)

Description

ABSTRACT:

In November 2017, the FDA approved the Abilify MyCite system. This drug-device combination product consists of aripiprazole tablets with an ingestible event marker (IEM) sensor and a wearable sensor patch that detects the signal from the IEM sensor after ingestion, which in turn transmits data to a smartphone application. Patients can use a Web-based portal to allow monitoring by healthcare professionals and caregivers for the purpose of tracking drug ingestion and adherence. Although this new digital technology provides a means to potentially enhance adherence and yield better patient health outcomes, ethical issues may arise for both patients and providers. US Pharm. 2019;44(7):22-24.

Augments

Tracking, Monitoring, Treating

Technology Keywords

Ingestible Event Marker (IEM) Sensor, Web Portal, Wireless Connectivity, Smartphone Applications, Digital Medicine, Digital Pills, Patch, Remote Monitoring, Remote Patient Monitoring

Keywords

Health, Ethics, Pharmaceuticals, Medical, Patients, Privacy

Marketing Keywords

Abilify MyCite, Otsuka Pharmaceutical, Bluetooth

Source

https://www.uspharmacist.com/article/the-promise-and-pitfalls-of-digital-medication